-
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
•
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink Bioscience, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). This strategic move is set to enhance Eli Lilly’s capabilities in developing innovative oncology treatments through Mablink’s advanced ADC technology. Mablink’s Proprietary ADC TechnologyMablink Bioscience’s…
